Cargando…

Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells

Cancer stem cells (CSCs) express high levels of drug efflux transporters and antioxidant genes, and are therefore believed to be responsible for cancer recurrence following chemo/radiotherapy intervention. In this study, we investigated the role of NF-E2-related factor 2 (NRF2), a master regulator o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryoo, In-geun, Choi, Bo-hyun, Kwak, Mi-Kyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480743/
https://www.ncbi.nlm.nih.gov/pubmed/25717032
_version_ 1782378186144743424
author Ryoo, In-geun
Choi, Bo-hyun
Kwak, Mi-Kyoung
author_facet Ryoo, In-geun
Choi, Bo-hyun
Kwak, Mi-Kyoung
author_sort Ryoo, In-geun
collection PubMed
description Cancer stem cells (CSCs) express high levels of drug efflux transporters and antioxidant genes, and are therefore believed to be responsible for cancer recurrence following chemo/radiotherapy intervention. In this study, we investigated the role of NF-E2-related factor 2 (NRF2), a master regulator of antioxidant gene expression, in the growth and stress resistance of CSC-enriched mammosphere. The MCF7 mammospheres expressed significantly higher levels of the NRF2 protein and target gene expression compared to the monolayer. As underlying mechanisms, we observed that proteolytic activity and expression of the proteasome catalytic subunits were decreased in the mammospheres. Additionally, mammospheres retained a high level of p62 and the silencing of p62 was observed to attenuate NRF2 activation. NRF2 increase was confirmed in sphere-cultures of the colon and ovarian cancer cells. The functional implication of NRF2 was demonstrated in NRF2-knockdown mammospheres. NRF2-silenced mammospheres demonstrated increased cell death and retarded sphere growth as a result of target gene repression. Moreover, unlike the control mammospheres, NRF2-knockdown mammospheres did not develop anticancer drug resistance. Collectively, these results indicated that altered proteasome function and p62 expression caused NRF2 activation in CSC-enriched mammospheres. In addition, NRF2 appeared to play a role in CSC survival and anticancer drug resistance.
format Online
Article
Text
id pubmed-4480743
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-44807432015-06-26 Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells Ryoo, In-geun Choi, Bo-hyun Kwak, Mi-Kyoung Oncotarget Research Paper Cancer stem cells (CSCs) express high levels of drug efflux transporters and antioxidant genes, and are therefore believed to be responsible for cancer recurrence following chemo/radiotherapy intervention. In this study, we investigated the role of NF-E2-related factor 2 (NRF2), a master regulator of antioxidant gene expression, in the growth and stress resistance of CSC-enriched mammosphere. The MCF7 mammospheres expressed significantly higher levels of the NRF2 protein and target gene expression compared to the monolayer. As underlying mechanisms, we observed that proteolytic activity and expression of the proteasome catalytic subunits were decreased in the mammospheres. Additionally, mammospheres retained a high level of p62 and the silencing of p62 was observed to attenuate NRF2 activation. NRF2 increase was confirmed in sphere-cultures of the colon and ovarian cancer cells. The functional implication of NRF2 was demonstrated in NRF2-knockdown mammospheres. NRF2-silenced mammospheres demonstrated increased cell death and retarded sphere growth as a result of target gene repression. Moreover, unlike the control mammospheres, NRF2-knockdown mammospheres did not develop anticancer drug resistance. Collectively, these results indicated that altered proteasome function and p62 expression caused NRF2 activation in CSC-enriched mammospheres. In addition, NRF2 appeared to play a role in CSC survival and anticancer drug resistance. Impact Journals LLC 2015-02-27 /pmc/articles/PMC4480743/ /pubmed/25717032 Text en Copyright: © 2015 Ryoo et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Ryoo, In-geun
Choi, Bo-hyun
Kwak, Mi-Kyoung
Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells
title Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells
title_full Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells
title_fullStr Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells
title_full_unstemmed Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells
title_short Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells
title_sort activation of nrf2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480743/
https://www.ncbi.nlm.nih.gov/pubmed/25717032
work_keys_str_mv AT ryooingeun activationofnrf2byp62andproteasomereductioninsphereformingbreastcarcinomacells
AT choibohyun activationofnrf2byp62andproteasomereductioninsphereformingbreastcarcinomacells
AT kwakmikyoung activationofnrf2byp62andproteasomereductioninsphereformingbreastcarcinomacells